查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1611986

急性护理综合症检测市场：按疾病类型、目标、样本类型和最终用户 - 2025-2030 年全球预测

Acute Care Syndromic Testing Market by Disease Type (Gastrointestinal Diseases, Genitourinary Diseases, Respiratory Diseases), Target (Bacteria, Fungi, Parasites), Sample Type, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023 年，急性护理综合症检测市场价值为 34 亿美元，预计到 2024 年将达到 37.4 亿美元，复合年增长率为 9.99%，到 2030 年将达到 66.3 亿美元。

急性护理症候群检测是指使用诊断测试，同时检测一个样本中的多种病原体，并提供快速、全面的结果，这对于急性护理环境中的快速决策至关重要。感染疾病日益流行以及需要及时、准确的诊断以优化治疗和改善患者的治疗结果推动了对此类检测的需求。其应用范围广泛，包括急诊室、重症监护室和加护病房，其中快速病原体识别对治疗通讯协定有重大影响。最终用途多种多样，包括医院、诊断中心和研究机构，展示了广泛采用的潜力。

主要市场统计
基准年[2023] 34亿美元
预测年份 [2024] 37.4亿美元
预测年份 [2030] 66.3亿美元
复合年增长率（%） 9.99%

市场成长受到分子诊断技术进步、人工智慧整合以增强预测分析以及人们对早期精确诊断益处的认识不断增强等因素的影响。感染疾病率的上升、对创新诊断的监管支持以及医疗保健支出的增加进一步推动了需求。新的发展机会在于开发低成本便携式诊断设备，以及在偏远和资源匮乏的地区扩大检测范围，在这些地区，获得医疗保健服务是一项重大挑战。

然而，市场面临先进诊断工具成本高、监管要求严格以及测试标准化潜在问题等限制。此外，操作方面的挑战也很多，因为需要训练有素的人员来操作复杂的设备并解释结果，这影响了采用率，特别是在发展中地区。

急性护理综合症测试的创新应侧重于提高测试特异性、缩短週转时间以及将照护现场设备与数位健康平台相结合以促进远端监控和咨询。持续研究病原体的演化模式对于确保更新针对新出现威胁的有效诊断解决方案至关重要。在技​​术进步和不断变化的医疗保健需求的推动下，市场格局是动态的。这表明相关人员支持创新、进行公共卫生工作合作以及解决市场渗透障碍的环境已经成熟。

市场动态：快速发展的急性护理症候群检测市场的关键市场洞察

供需的动态交互作用正在改变急性护理综合症检测市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 感染疾病爆发增加
    • 利用综合症测试来检测抗菌药物抗药性
    • 政府扩大性行为感染传染病治疗和诊断的倡议
  • 市场限制因素
    • 假阳性/假阴性的发生与污染的可能性
  • 市场机会
    • 努力将症状检测纳入管理计划
    • 临床微生物学的进步导致检测策略的改进
  • 市场挑战
    • 急性医学综合症检测方法的技术局限性

波特五力：驾驭急诊症候群侦测市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解急性照护症候群检测市场的外部影响

外部宏观环境因素在塑造急性护理症候群检测市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解急性医学症候群检测市场的竞争状况

急性护理综合症测试市场的详细市场占有率分析提供了对供应商绩效的全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵急性护理症候群测试市场供应商的绩效评估

FPNV 定位矩阵是评估急性护理症候群检测市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，为急诊症候群检测市场的成功指明道路

对于旨在加强其在全球市场的影响力的公司来说，对急性护理综合症检测市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 感染疾病率增加
      • 使用症状测试检测抗菌药物抗药性
      • 政府努力扩大性行为感染传染病的治疗和诊断
    • 抑制因素
      • 假阳性和阴性的发生率以及污染的可能性
    • 机会
      • 将综合症测试纳入管理计划的努力
      • 临床微生物学的进步改进了检测策略
    • 任务
      • 急性护理综合症检测方法的技术局限性
  • 市场区隔分析
    • 疾病类型：污染程度的增加和气候模式的变化导致呼吸道疾病的盛行率急剧上升
    • 目标：需要及时、快速诊断急诊环境中的细菌感染疾病
    • 样本类型：利用血液样本促进感染疾病和败血症的检测
    • 最终用户：增加私人投资和政府努力升级医院基础设施
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 急性医学症状检测市场：依疾病类型

  • 消化系统疾病
  • 泌尿系统疾病
  • 呼吸系统疾病
  • 热带疾病

第七章 急性医学症状检测市场目标

  • 细菌
  • 真菌
  • 寄生虫
  • 病毒

第八章依样本类型分類的急诊症候群检测市场

  • 生物体液
  • 血
  • 凳子
  • 棉花棒
  • 尿

第九章 急性医学症候群检测市场：依最终使用者分类

  • 临床和诊断实验室
  • 医院
  • 研究/学术机构

第十章美洲急性医学症检测市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区急性医学症候群检测市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的急性医学症候群检测市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • FDA核准针对 COVID-19 的家庭抗原测试
    • 拜登政府提供美国家庭免费新冠病毒检测，向国内製造商投资6亿美元
    • NIH 推出居家测试作为 COVID-19远端医疗计划试点
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Applied BioCode, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biocartis NV
  • BIOHM Health LLC
  • bioMerieux SA
  • Curetis GmbH by OpGen, Inc
  • CVS Health
  • Danaher Corporation
  • DiaSorin SpA
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd
  • Genetic Signatures Ltd.
  • Hologic Inc.
  • Luminex Corporation
  • Microbiologics, Inc.
  • Pfizer, Inc.
  • QIAGEN NV
  • QuantuMDx Group Ltd.
  • Seegene Inc.
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Werfen
Product Code: MRR-5A3042B3D68E

The Acute Care Syndromic Testing Market was valued at USD 3.40 billion in 2023, expected to reach USD 3.74 billion in 2024, and is projected to grow at a CAGR of 9.99%, to USD 6.63 billion by 2030.

Acute care syndromic testing refers to the use of diagnostic tests that simultaneously detect multiple pathogens from a single sample, offering rapid and comprehensive results essential for quick decision-making in acute care settings. This testing is necessary due to the increasing prevalence of infectious diseases and the need for timely and accurate diagnosis to optimize treatment and improve patient outcomes. Applications are wide-ranging, including emergency rooms, urgent care, and intensive care units, where rapid pathogen identification can significantly impact treatment protocols. The end-use scope spans hospitals, diagnostic centers, and research institutes, underscoring its broad adoption potential.

KEY MARKET STATISTICS
Base Year [2023] USD 3.40 billion
Estimated Year [2024] USD 3.74 billion
Forecast Year [2030] USD 6.63 billion
CAGR (%) 9.99%

Market growth is influenced by factors such as advancements in molecular diagnostic technologies, the integration of AI for enhanced predictive analytics, and growing awareness about the benefits of early and precise diagnostics. The rising incidence of infectious outbreaks, regulatory support for innovative diagnostics, and increasing healthcare spending further drive demand. Emerging opportunities lie in developing low-cost, portable diagnostic devices and expanding testing into remote and resource-poor settings, where accessibility significantly challenges healthcare delivery.

However, the market faces limitations such as high costs of advanced diagnostic tools, stringent regulatory requirements, and potential issues with test standardization. Moreover, the necessity for trained personnel to operate sophisticated equipment and interpret results adds to operational challenges, impacting adoption rates, especially in developing regions.

Innovation in acute care syndromic testing should focus on enhancing test specificity, reducing turnaround times, and integrating point-of-care devices with digital health platforms to facilitate remote monitoring and consultation. Continuous research into pathogen evolution patterns is essential to ensure effective diagnostic solutions remain updated for emerging threats. The nature of the market is dynamic, driven by technological advancements and evolving healthcare needs, indicating a vibrant landscape ripe for stakeholders to support innovation, collaborate on public health initiatives, and tackle the barriers hindering widespread market penetration.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Acute Care Syndromic Testing Market

The Acute Care Syndromic Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of infectious disease outbreaks
    • Utilization of syndromic tests for detecting antimicrobial resistance
    • Government initiatives to expand treatment and diagnosis of sexually transmitted diseases
  • Market Restraints
    • Incidences of false positives and false negatives and chances of contamination
  • Market Opportunities
    • Efforts to include syndromic testing under stewardship programs
    • Advancements in clinical microbiology leading to improved testing strategies
  • Market Challenges
    • Technical limitations of acute care syndromic testing methods

Porter's Five Forces: A Strategic Tool for Navigating the Acute Care Syndromic Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Acute Care Syndromic Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Acute Care Syndromic Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Acute Care Syndromic Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Acute Care Syndromic Testing Market

A detailed market share analysis in the Acute Care Syndromic Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Acute Care Syndromic Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Acute Care Syndromic Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Acute Care Syndromic Testing Market

A strategic analysis of the Acute Care Syndromic Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Acute Care Syndromic Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Applied BioCode, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biocartis NV, BIOHM Health LLC, bioMerieux SA, Curetis GmbH b y OpGen, Inc, CVS Health, Danaher Corporation, DiaSorin S.p.A, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, Genetic Signatures Ltd., Hologic Inc., Luminex Corporation, Microbiologics, Inc., Pfizer, Inc., QIAGEN N.V., QuantuMDx Group Ltd., Seegene Inc., Siemens Healthineers AG, Sysmex Corporation, Thermo Fisher Scientific Inc., and Werfen.

Market Segmentation & Coverage

This research report categorizes the Acute Care Syndromic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Gastrointestinal Diseases, Genitourinary Diseases, Respiratory Diseases, and Tropical Diseases.
  • Based on Target, market is studied across Bacteria, Fungi, Parasites, and Viruses.
  • Based on Sample Type, market is studied across Biofluids, Blood, Stool, Swabs, and Urine.
  • Based on End User, market is studied across Clinical & Diagnostic Laboratories, Hospitals, and Research & Academic Institutions.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of infectious disease outbreaks
      • 5.1.1.2. Utilization of syndromic tests for detecting antimicrobial resistance
      • 5.1.1.3. Government initiatives to expand treatment and diagnosis of sexually transmitted diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Incidences of false positives and false negatives and chances of contamination
    • 5.1.3. Opportunities
      • 5.1.3.1. Efforts to include syndromic testing under stewardship programs
      • 5.1.3.2. Advancements in clinical microbiology leading to improved testing strategies
    • 5.1.4. Challenges
      • 5.1.4.1. Technical limitations of acute care syndromic testing methods
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Disease Type: Growing pollution levels and changing climate patterns leading to a surge in the prevalence of respiratory diseases
    • 5.2.2. Target: Need for timely and rapid diagnosis of bacterial infections in acute care settings
    • 5.2.3. Sample Type: Utilization of blood samples to facilitate detection of infections and sepsis
    • 5.2.4. End User: Expanding private investments and government initiatives to upgrade hospital infrastructure
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Acute Care Syndromic Testing Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Gastrointestinal Diseases
  • 6.3. Genitourinary Diseases
  • 6.4. Respiratory Diseases
  • 6.5. Tropical Diseases

7. Acute Care Syndromic Testing Market, by Target

  • 7.1. Introduction
  • 7.2. Bacteria
  • 7.3. Fungi
  • 7.4. Parasites
  • 7.5. Viruses

8. Acute Care Syndromic Testing Market, by Sample Type

  • 8.1. Introduction
  • 8.2. Biofluids
  • 8.3. Blood
  • 8.4. Stool
  • 8.5. Swabs
  • 8.6. Urine

9. Acute Care Syndromic Testing Market, by End User

  • 9.1. Introduction
  • 9.2. Clinical & Diagnostic Laboratories
  • 9.3. Hospitals
  • 9.4. Research & Academic Institutions

10. Americas Acute Care Syndromic Testing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Acute Care Syndromic Testing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Acute Care Syndromic Testing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA Clears COVID-19 Home Antigen Test
    • 13.3.2. Biden Government to Deliver Free COVID Tests To U.S. Households And Invest USD 600 Million In Domestic Manufacturers
    • 13.3.3. NIH Launches Home Test to Treat a Pilot COVID-19 Telehealth Program
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Applied BioCode, Inc.
  • 3. Becton, Dickinson and Company
  • 4. Bio-Rad Laboratories, Inc.
  • 5. Biocartis NV
  • 6. BIOHM Health LLC
  • 7. bioMerieux SA
  • 8. Curetis GmbH b y OpGen, Inc
  • 9. CVS Health
  • 10. Danaher Corporation
  • 11. DiaSorin S.p.A
  • 12. Eurofins Scientific SE
  • 13. F. Hoffmann-La Roche Ltd
  • 14. Genetic Signatures Ltd.
  • 15. Hologic Inc.
  • 16. Luminex Corporation
  • 17. Microbiologics, Inc.
  • 18. Pfizer, Inc.
  • 19. QIAGEN N.V.
  • 20. QuantuMDx Group Ltd.
  • 21. Seegene Inc.
  • 22. Siemens Healthineers AG
  • 23. Sysmex Corporation
  • 24. Thermo Fisher Scientific Inc.
  • 25. Werfen

LIST OF FIGURES

  • FIGURE 1. ACUTE CARE SYNDROMIC TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ACUTE CARE SYNDROMIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ACUTE CARE SYNDROMIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ACUTE CARE SYNDROMIC TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ACUTE CARE SYNDROMIC TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GENITOURINARY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TROPICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY FUNGI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PARASITES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRUSES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BIOFLUIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY STOOL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SWABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CLINICAL & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 195. ACUTE CARE SYNDROMIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 196. ACUTE CARE SYNDROMIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023